ClinicalTrials.gov
public full text
Public Domain
Neurofilaments for NEDA Assessing in MS
Goal is to evaluate the achievement of biological NEDA as demonstrated by a drop in neurofilament levels in MS patients commencing Alemtuzumab therapy as part of their MS management.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Relıabılıty and valıdıty of the Two-minute Test wıth Multiple Sclerosis#913296
- Safety of Exposure to Natalizumab During Pregnancy#887987
- Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.#1171454
- Feasibility of Neuromodulation With Connectivity-Guided iTBS for Cognitive Impairment in MS#846268
- Effects of tDCS and Cognitive Rehabilitation on Cognition and Neural Plasticity in MS Patients#1057054
Record · ID 904874
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive